Aspire Biopharma Holdings, Inc. (ASBP)

Aspire Biopharma Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-17.02	-1.31	-0.36	-0.6
Change in Accounts Payable	1.41	0.25	0.05	0.1
Change in Other Net Operating Assets	-0.73	0.8	0.32	0.35
Operating Cash Flow	-1.82	-0.27	0.01	-0.14
Sale (Purchase) of Intangibles	-	-	-	-4.9
Investing Cash Flow	-	-	-	-4.9
Issuance of Common Stock	-	-	-	1
Other Financing Activities	0.27	-	-	3.85
Financing Cash Flow	3.12	0.26	-	4.85
Net Cash Flow	1.3	-0.01	0.01	-0.19
Cash Income Tax Paid	0	0	-	-
Levered Free Cash Flow	-	-0.68	-0.19	-
Unlevered Free Cash Flow	-	-0.62	-0.19	-
Change in Working Capital	0.68	1.04	0.37	0.45

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q